About ProJenX

ProJenX is a clinical stage biotechnology company with novel, brain-penetrant, targeted therapies to address debilitating brain diseases, with an initial focus on amyotrophic lateral sclerosis (ALS).

ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University in order to rapidly develop and commercialize its lead therapeutic candidate, prosetin, for people with ALS. Prosetin is an oral, brain-penetrant, MAP4 kinase inhibitor targeting endoplasmic reticulum (ER) stress-mediated motor neuron death.

At the heart of ProJenX’s approach is an innovative, patient-specific, cell-based drug discovery platform that can be leveraged to identify targeted, small molecule therapies for ALS and other currently untreatable brain diseases.


May 18, 2022 –ProJenX Names Life Sciences Industry Veteran Stan E. Abel as CEO

March 1, 2022 – ProJenX Announces First Person Dosed in Phase 1 Study of Prosetin

February 16, 2022 – ProJenX Launches to Advance Novel, Targeted Therapies for ALS and Other Brain Diseases

We’re just getting started

More information coming soon— in the meantime, contact us to receive updates from ProJenX.

Contact Us